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INTRODUCTION
Methicillin-susceptible Staphylococcus aureus (MSSA), Strep-
tococcus pyogenes, Streptococcus pneumoniae and Haemophilus in-
fluenzae are major causative pathogens of respiratory infec-
tious disease and established causes of pneumonia, otitis media
and paranasal sinusitis. In Japan and other Asian countries,
S. pneumoniae has been rapidly developing  -lactam resistance
by amino-acid substitutions in penicillin-binding proteins
(PBPs). Isolates of these new strains also frequently show resis-
tance to macrolides conferred by macrolide-resistant genes
(1-3). Macrolide resistance in S. pneumoniae is conferred by
23S ribosome methylation by ErmB and/or drug efflux sys-
tems by MefA (4). Similarly, encounters with ermA-, ermB-,
ermC- or mefA-positive MSSA and S. pyogenes have been grow-
ing more common in clinical settings. Clinicians in Japan
have also been isolating new strains of H. influenzae, -lac-
tamase-negative ampicillin resistant strains (BLNAR), with
increasing frequency (1, 5). Taking all of these developments
together, it seems certain that respiratory pathogens are acquir-
ing  -lactam and macrolide resistance. This makes it all the
more important to examine the antibacterial activity against
multidrug-resistant bacteria isolated from patients with res-
piratory tract infections (2, 5-9).
In this study we examine the in vitro activities of 7 antibiotics,
oral cephems (cefditoren, cefcapene and cefdinir), macrolide
(erythromycin), ketolide (telithromycin) and controls (ben-
zylpenicillin and ampicillin) against clinical isolates of four
major respiratory pathogens (MSSA, S. pyogenes, S. pneumoniae,
and H. influenzae) collected in Japan between 2002 and 2003.
MATERIALS AND METHODS
Clinical isolates
MSSA, S. pyogenes, S. pneumoniae and H. influenzae, which
were isolated from the respiratory tract and collected at 66
institutions (20 university hospitals; 34 local central hospi-
tals; 4 clinics; 8 general practitioners) in all over the Japan
between 2002 and 2003, were used in this study. Forty-three
isolates of MSSA and 49 isolates of S. pyogenes strains were
randomly selected. S. pneumoniae was classified in three cate-
gories, based on the mutations of the pbp genes associated with
-lactam resistance. As a result, the following isolates were
studied: 34 isolates of genotypic penicillin-susceptible S. pneu-
moniae (gPSSP) with no mutations in the pbp1a, 2x or 2b genes;
47 isolates of genotypic penicillin-intermediate-resistant S.
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In vitro Activities of Oral Cephem and Telithromycin Against Clinical
Isolates of Major Respiratory Pathogens in Japan
The in vitro antibacterial activities of oral cephem antibiotics and ketolide telithromycin
against major respiratory pathogens possessing  -lactam-resistant mutations (with-
in the pbp gene) and/or macrolide-resistant genes (erm and mef) were examined
in clinical isolates collected at 66 institutes in all over the Japan between 2002 and
2003. Telithromycin showed the strongest antibacterial activity against methicillin-
susceptible Staphylococcus aureus strains with and without macrolide-resistant
genes, such as ermA or ermC gene. All the cephem antibiotics showed potent anti-
bacterial activity against Streptococcus pyogenes, with minimum inhibitory concentra-
tions (MICs) of 0.015 mg/L or lower. Cefdinir had a much higher MIC90 against geno-
typic penicillin-resistant Streptococcus pneumoniae (gPRSP) than cefditoren and
cefcapene (8 mg/L cefdinir vs. 1 mg/L cefditoren and cefcapene). The majority of
gPRSP harbored either ermB or mefA, and the antibacterial activity of telithromycin
against these strains was decreased however some susceptibility was still sustained.
Cefditoren exerted the strongest antibacterial activity against  -lactamase-nega-
tive ampicillin-resistant Haemophilus influenzae, with an MIC90 of 0.5 mg/L. These
results underline the importance of checking the susceptibility and selecting an appro-
priate antibiotic against target pathogens.
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pneumoniae (gPISP) with mutations in two of three pbp genes
(1a and 2x, 1a and 2b or 2x and 2b) and 68 isolates of geno-
typic penicillin-resistant S. pneumoniae (gPRSP) with muta-
tions in all three pbp genes, as described by Ubukata et al. (9).
The H. influenzae isolates were classified into two variants. The
first, BLNAR, had M377I, S385T, L389F and N526K muta-
tions of the ftsI gene encoding PBP3 without carrying the
TEM-1 gene encoding  -lactamase. The second,  -lactamase-
negative ampicillin-susceptible H. influenzae (BLNAS) had
no mutations of the ftsI gene and did not carry the TEM-1
gene. Twenty-five BLNAS isolates and 24 BLNAR isolates
were selected for inclusion in this study.
Detection of drug-resistance genes by PCR
Mutations in the pbp1a, 2x and 2b genes and the presence
of the mefA and ermB genes in S. pneumoniae were detected by
a penicillin-resistant S. pneumoniae detection kit (Wakunaga
Pharmaceutical, Osaka, Japan). Mutations in the ftsI gene
and the presence of the TEM-1 gene in H. influenzae were
detected using an H. influenzae gene detection kit (Wakuna-
ga Pharmaceutical). The presence of the ermA and ermC genes
in MSSA, and the presence of the mefA and ermB genes in S.
pyogenes, were detected by conventional PCR methods (6, 10).
Antibiotic susceptibility test
Cefditoren and ampicillin were supplied by Meiji Seika
Kaisha, Ltd., Tokyo, Japan. Cefdinir was purchased from
Kemprotec Ltd., Middlesborough, U.K. Erythromycin and
benzylpenicillin was purchased from Sigma-Aldrich Japan.
Cefcapene was synthesized in our laboratory. Telithromycin
was purified from the commercial product (Aventis Pharma
Japan, Tokyo, Japan). Minimum inhibitory concentrations
(MICs) were determined by the agar dilution method with
2-fold serial dilutions of antibiotics. The following Mueller-
Hinton agar (MHA, Becton, Dickinson and Company, Sparks,
MD, U.S.A.) preparations were used for the drug suscepti-
bility tests: MHA alone for MSSA; MHA supplemented with
5% defibrinated equine blood for S. pneumoniae; MHA sup-
plemented with 5% defibrinated equine blood heated until
chocolate for H. influenzae, and MHA supplemented with 5%
defibrinated ovine blood for S. pyogenes. Each isolate was inoc-
ulated at 104 CFU/spot on each agar plate. The MIC was de-
termined as the minimum drug concentration showing no
bacterial growth after 18-20 hr of incubation at 35℃. S. au-
reus ATCC29213, S. pneumoniae ATCC49619, H. influenzae
ATCC49247 and ATCC49766 were used to control the accu-
racy of the MIC determinations. S. pneumoniae ATCC49619
was used as a control in the measurement of the susceptibil-
ity of S. pyogenes isolates. As for the breakpoint values of anti-
biotics for pneumoniae, we referred to the section of pneumo-
niae in the journal issued by the Sensitivity Determination
Committee for Antibiotics, Japanese Society of Chemother-
apy, except for benzylpenicillin that was not provided this
journal. Judging from the breakpoint value, we calculated
the resistance or susceptibility rate of each antibitotic against
pathogens.
RESULTS
Antibacterial activity against MSSA
Of the 43 MSSA isolates used in this study, 10 isolates (23.3
%) and 3 isolates (7.0%) carried either ermA or ermC, respec-
tively, while none of the strains carried both genes. Telithro-
mycin showed the most potent antibacterial activity against
MSSA, followed by cefdinir, cefditoren, and cefcapene in des-
cending order (Table 1). The antibacterial activity of erythro-
mycin against MSSA was markedly attenuated by the pres-
ence of the erm genes, whereas the MIC90 of telithromycin was
only 0.06 mg/L, even in the presence of the erm genes, with
no cross-resistance to erythromycin.
Macrolide-resistant 
gene
No. of
strains
Drug
Minimum inhibitory concentration (MIC) (mg/L)
Range MIC50 MIC90
Breakpoint
(mg/L)*
Resistance-
rate (%)
ermA or ermC 13 Cefditoren 1 1 1 1 0
Cefcapene 1-2 1 2 0.5 100
Cefdinir 0.25-0.5 0.5 0.5 1 0
Erythromycin 1->128 8 >128 0.5 100
Telithromycin 0.03-0.13 0.06 0.13 2 0
None 30 Cefditoren 0.5-1 1 1 1 0
Cefcapene 1.-2 1 2 0.5 100
Cefdinir 0.25-1 0.5 0.5 1 0
Erythromycin 0.13-32 0.25 0.25 0.5 3.3
Telithromycin 0.015-0.13 0.06 0.06 2 0
Table 1. Antibacterial activity of oral cephems, erythromycin and telithromycin against methicillin-susceptible Staphylococcus aureus
(MSSA)
*, Breakpoint value of each antibiotic for pneumoniae was cited from the journal issued by that was defined by the Sensitivity Determination Committee
for Antibiotics, Japanese Society of Chemotherapy.22 A. Shimizu, K. Maebashi, M. Niida, et al.
Antibacterial activity against S. pyogenes
As shown in Table 2, 6 isolates (12.2%) and 17 isolates
(34.7%) of the S. pyogenes strains carried the ermB and mefA
genes, respectively. The MIC of the cephem antibiotics was
no more than 0.015 mg/L against all the isolates of S. pyo-
genes tested. The MIC90 of telithromycin was increased when
the isolates carried either ermB or mefA. Especially high resis-
tance against telithromycin (MIC=64 mg/L) was observed
in 4 of 6 isolates carrying the ermB gene.
Antibacterial activity against S. pneumoniae
Subdivision of the gPSSP, gPISP, and gPRSP strains based
on the presence of the ermB and mefA genes revealed that S.
pneumoniae carried either ermB or mefA at a high frequency
(Table 3). The  -lactams showed potent antibacterial activi-
ty against gPSSP, and cefditoren showed the strongest anti-
bacterial activity against gPSSP, gPISP, and gPRSP of all 3
-lactam antibiotics. The presence of the ermB and mefA genes
within S. pneumoniae strains did not affect the activity the  -
lactams. Telithromycin and erythromycin showed no attenu-
ation in antibacterial activity even in the presence of a mutat-
ed pbp gene, while telithromycin exerted the strongest antibac-
terial activities against all three of the S. pneumoniae strains.
However, the antibacterial activity of telithromycin was wea-
kened in the presence of either the ermB or mefA gene.
Antibacterial activity against H. influenzae
Cefditoren and cefcapene showed stronger antibacterial
activity than cefdinir, telithromycin, and erythromycin against
BLNAS (Table 4). The antibacterial activities of the oral ce-
phems were weaker against BLNAR than against BLNAS,
whereas the MIC90 of cefditoren was 0.5 mg/L, the most potent
level measured among all the antibiotics tested in this study.
Telithromycin showed an equal MIC90 against BLNAR and
BLNAS, and the same result was obtained for erythromycin.
DISCUSSION
The incidence of drug-resistant pathogens differs greatly
between countries, presumably in accordance with differences
in the dosage and usage of antibiotics. In this study we focused
on the antibacterial activities of three different types of antibi-
otics (cephem, macrolide and ketolide) against recently iso-
lated pathogens from respiratory tract infections carrying var-
ious drug-resistance genes in the Japanese population. The
different frequencies of drug-resistant pathogens between Japan
and neighboring Asian countries have also been considered. 
In S. aureus, ribosome methylation and the presence of drug
efflux systems have been shown to confer resistance against
macrolide antibiotics (4). The isolates that exhibited low sus-
ceptibility to erythromycin without the erm gene in this study
may have overexpressed multidrug efflux systems such as
MsrA (11). Interestingly, all MSSA strains examined in this
study were susceptible to telithromycin, even when they were
positive for the presence of the erm gene. The expression of
the erm gene can be inducible or constitutive, and MSSA is
resistant to telithromycin when the expression is constitutive
(12). Thus, we know that the isolates used in this study might
harbor the inducible type of gene expression. The rate of MSSA
resistance to telithromycin in Asia, 20%, is higher than the
rates in Europe and the U.S.A. (13).
-lactam resistance has not yet been reported in S. pyogenes,
Macrolide-resistant 
gene
No. of
strains
Drug
MIC (mg/L)
Range MIC50 MIC90
Breakpoint
(mg/L)*
Resistance
-rate (%)
ermB 6 Cefditoren 0.008-0.015 -- 10
Cefcapene 0.008-0.015 -- 0.5 0
Cefdinir 0.008-0.015 -- 10
Erythromycin 1->128 -- 0.5 100
Telithromycin 0.06-64 -- 2 66.7
mefA 17 Cefditoren 0.008-0.015 0.008 0.015 1 0
Cefcapene 0.008-0.015 0.008 0.015 0.5 0
Cefdinir 0.008-0.015 0.008 0.015 1 0
Erythromycin 8-32 16 32 0.5 100
Telithromycin 0.5-2 1 1 2 0
None 26 Cefditoren 0.008-0.015 0.008 0.015 1 0
Cefcapene 0.008-0.015 0.008 0.015 0.5 0
Cefdinir 0.008-0.015 0.008 0.015 1 0
Erythromycin 0.03-0.25 0.06 0.13 0.5 0
Telithromycin 0.015-0.06 0.015 0.03 2 0
Table 2. Antibacterial activity of oral cephems, erythromycin and telithromycin against Streptococcus pyogenes
*, Breakpoint value of each antibiotic for pneumoniae was cited from the journal issued by that was defined by the Sensitivity Determination Committee
for Antibiotics, Japanese Society of Chemotherapy.Antibacterial Activity of Oral Cephems and Ketolide Telithromycin 23
Organism macrolide- 
resistant gene
No. of
strains
Drug
Minimum inhibitory concentration (MIC) (mg/L)
Range MIC50 MIC90
Breakpoint
(mg/L)*
Resistance
-rate (%)
gPSSP 7 Cefditoren 0.008-0.03 --10
ermB Cefcapene 0.008-0.06 --0.5 0
Cefdinir 0.03-0.13 --10
Erythromycin >128 --0.5 100
Telithromycin 0.03-1 --20
Benzylpenicillin 0.004-0.03 ----
gPSSP 3 Cefditoren 0.008-0.03 --10
mefA Cefcapene 0.008-0.06 --0.5 0
Cefdinir 0.03-0.06 --10
Erythromycin 4-8 --0.5 100
Telithromycin 0.06-0.13 --20
Benzylpenicillin 0.004-0.015 ----
gPSSP 24 Cefditoren 0.004-0.03 0.015 0.03 1 0
None Cefcapene 0.004-0.13 0.008 0.06 0.5 0
Cefdinir 0.03-0.13 0.03 0.13 1 0
Erythromycin 0.06-0.25 0.13 0.13 0.5 0
Telithromycin 0.008-0.06 0.008 0.015 2 0
Benzylpenicillin 0.004-0.015 0.015 0.015 --
gPISP
� 22 Cefditoren 0.03-0.25 0.13 0.13 1 0
ermB Cefcapene 0.03-0.5 0.13 0.25 0.5 0
Cefdinir 0.03-0.5 0.13 0.5 1 0
Erythromycin 128->128 >128 >128 0.5 100
Telithromycin 0.03-1 0.13 0.5 2 0
Benzylpenicillin 0.015-0.25 0.03 0.25 --
gPISP
� 8 Cefditoren 0.13-1 --10
mefA Cefcapene 0.13-1 --0.5 25
Cefdinir 0.25-2 --12 5
Erythromycin 1->128 --0.5 100
Telithromycin 0.06-1 --20
Benzylpenicillin 0.06-0.25 ----
gPISP 17 Cefditoren 0.03-0.5 0.25 0.5 1 0
None Cefcapene 0.03-2 0.5 0.5 0.5 11.8
Cefdinir 0.06-2 2 2 1 64.7
Erythromycin 0.06-1 0.13 0.13 0.5 5.9
Telithromycin 0.008-0.13 0.015 0.03 2 0
Benzylpenicillin 0.03-0.5 0.25 0.5 --
gPRSP
� 22 Cefditoren 0.25-1 0.5 1 1 0
ermB Cefcapene 0.25-1 0.5 1 0.5 45.5
Cefdinir 1-8 4 8 1 95.5
Erythromycin 128->128 >128 >128 0.5 100
Telithromycin 0.03-1 0.06 0.13 2 0
Benzylpenicillin 0.5-4 1 2 --
gPRSP
� 38 Cefditoren 0.13-2 0.5 1 1 7.9
mefA Cefcapene 0.13-4 0.5 1 0.5 34.2
Cefdinir 0.5-8 4 8 1 92.1
Erythromycin 1->128 4 8 0.5 100
Telithromycin 0.06-1 0.13 0.25 2 0
Benzylpenicillin 0.5-4 1 2 --
gPRSP 8 Cefditoren 0.25-1 --10
None Cefcapene 0.5-1 --0.5 25
Cefdinir 2-8 --1 100
Erythromycin 0.06-0.13 --0.5 0
Telithromycin 0.015-0.03 --20
Benzylpenicillin 0.5-1 ----
Table 3. Antibacterial activity of  -lactams, erythromycin and telithromycin against Streptococcus pneumoniae
gPSSP, genotypic susceptible S. pneumoniae; gPISP, genotypic penicillin-intermediate-resistant S. pneumoniae; gPRSP, genotypic penicillin-resistant
S. pneumoniae. *, Breakpoint value of each antibiotic for pneumoniae was cited from the journal issued by that was defined by the Sensitivity Deter-
mination Committee for Antibiotics, Japanese Society of Chemotherapy; 
�
, Including one strain with both ermB and mefA genes.24 A. Shimizu, K. Maebashi, M. Niida, et al.
but macrolide-resistant strains of this pathogen have been
frequently isolated (6-8, 13, 14). Some of the S. pyogenes iso-
lates carrying ermB have become highly resistant to telithro-
mycin (MIC >32 mg/L) (6-8). In our study, telithromycin and
erythromycin showed reduced antibacterial activity against
S. pyogenes isolates carrying either ermB or mefA. The incidence
of telithromycin-resistant S. pyogenes (MIC ≥4 mg/L) differs
from region to region, presumably due to the different usage
of antibiotics. For example, the incidence in Japan stands at
less than 1%, while the incidences in Korea and Europe are
generally above 10% (13).
As previously reported, we categorized S. pneumoniae into
gPRSP or gPISP based on mutations in the pbp gene (9). ermB
and mefA have been found to be present at high frequencies
in recent Japanese isolates of PISP and PRSP (2, 3). Our results
also revealed many gPRSP and gPISP isolates carrying either
ermB or mefA. In Korea and Hong Kong, PRSP accounts for
≥60% of clinical isolates of S. pneumoniae, and 50% or more
of these isolates carry either ermB or mefA (3). It thus comes
as no surprise that the MIC of telithromycin has already risen
to 4 mg/L against newly emerging strains of S. pneumoniae
in Taiwan (15) and to 2-8 mg/L against strains in other coun-
tries (7).
Just as Japan is witnessing a rising prevalence of BLNAR
and falling prevalence of  -lactamase-producing strains, the
very opposite trends are being observed in Korea (1, 3). It
might be reasonable to assume that penicillin is more fre-
quently prescribed in Korea than in Japan. Accordingly, the
oral cephems such as cefditoren, an agent stable against  -
lactamase in H. influenzae, may be useful and effective in both
of these countries. Although macrolide-resistant genes such
as erm or mef have not yet been found in H. influenzae, the anti-
bacterial activity of telithromycin and erythromycin was lower
than that of cefditoren against the H. influenzae isolates ana-
lyzed in the present study. Peric et al. demonstrated that more
than 98% of H. influenzae strains have a macrolide efflux me-
chanism (16). Thus, the H. influenzae isolates investigated in
this study might also express efflux pumps, such as AcrAB
(17).
In conclusion, the variable antibacterial activity against the
clinical pathogens in the presence of drug-resistant genes
demonstrated in this study suggests that the inappropriate
prescription of antibiotic agents may lead to clinical failure.
It will be important to choose suitable antibiotics and to make
the most of the ability of the prescribed agents in order to pre-
vent the further emergence of drug-resistant pathogens.
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